Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
=== Bibliography === Arnheim, Daniel D. Dance Injuries: Their Prevention And Care. 3rd ed. Princeton, NJ: Princeton Book Company, 1991. Print. Ashley, Linda. Essential Guide to Dance. 2nd ed. London: Hodder & Stoughton, 2004. Print. ISBN 978-0340803202. Barratt, Marcia, et al. Foundations For Movement. Dubuque, IA: Wm. C. Brown Co., 1964. Print. Berardi, Gigi. Finding Balance. 2nd ed. Routledge, NY: Routledge, 2005. Print. ISBN 978-0415943390. Blakey, W P. Stretching Without Pain. Canada: Twin Eagles Educational & Healing Institute, 1994. Print. ISBN 978-1873017050. Como, William. Raoul Gelabert's anatomy for the dancer with exercises to improve technique and prevent injuries. New York: Danad, 1964; 51-57. ASIN B000XYUX4Q. Dilmen, Nevit. Stretching. 2009. Own Work. Wikimedia Commons. Web. 4 Dec. 2010. Franklin, Eric N. Conditioning for Dance. Champaign, IL: Human Kinetics, 2004. Print. FvS. Split, gymnastics. 2005. Own Work. Wikimedia Commons. Web. 4 Dec. 2010. Liedarback, "General considerations," p. 59. McCharles, Rick. Gymnast jumping on beam. 2008. https://www.flickr.com/photos/71035721@N00/2972933329. Wikimedia Commons. Web. 4 Dec. 2010. Pare, Caroline. Caroline Zhang in 2008 Skate Canada International. 2008. https://web.archive.org/web/20120724082853/http://everythingskating.com/. Wikimedia Commons. Web. 4 Dec. 2010. Reinking, Ann, and Linda Szmyd. The Dancer's Workout. London: Bantam Books, 1984. Print. Ryan, Allan J., and Robert E. Stephens, eds. The Healthy Dancer: Dance Medicine for Dancers. Princeton, NJ: Princeton Book Company, 1987. Print.
== Prevention of plant disease == Control of green mould initially relies on the proper handling of fruit before, during, and after harvesting. Spores can be reduced by removing fallen fruit. Risk of injury can be decreased in a variety of ways, including storing fruit in high humidity and low temperature conditions, and harvesting before irrigation or rainfall in order to minimize fruit susceptibility to peel damage. Degreening practices can also be conducted at humidities above 92% in order to heal injuries. Chemical control in the form of fungicides is also commonly used. Examples include imazalil, thiabendazole, and biphenyl, all of which suppress the reproductive cycle of P. digitatum. Post-harvest chemical treatment usually consists of washes conducted at 40–50 °C (104–122 °F), containing detergents, weak alkalines, and fungicides. California packing houses typically use a fungicide cocktail containing sodium o-phenylphenate, imazalil, and thiabendazole. In Australia, guazatine is commonly used, although this treatment is restricted to the domestic market. In terms of the export market, Generally recognized as safe (GRAS) substances are currently being explored as alternatives. GRAS substances such as sodium bicarbonate, sodium carbonate, and ethanol, have displayed an ability to control P. digitatum by decreasing germination rate. Resistance to common fungicides is currently combated through the use of other chemicals.
On March 10, 2023, Silicon Valley Bank (SVB) failed after a bank run, marking the third-largest bank failure in United States history and the largest since the 2008 financial crisis. It was one of three bank failures, along with Silvergate Bank and Signature Bank, in March 2023 in the United States. Seeking higher investment returns from its burgeoning deposits, SVB had dramatically increased its holdings of long-term securities since 2021, accounting for them on a hold-to-maturity basis. The market value of these bonds decreased significantly through 2022 and into 2023 as the Federal Reserve raised interest rates to curb an inflation surge, causing unrealized losses on the portfolio. Higher interest rates also raised borrowing costs throughout the economy and some Silicon Valley Bank clients started pulling money out to meet their liquidity needs. To raise cash to pay withdrawals by its depositors, SVB announced on Wednesday, March 8 that it had sold over US$21 billion worth of securities, borrowed $15 billion, and would hold an emergency sale of some of its treasury stock to raise $2.25 billion. The announcement, coupled with warnings from prominent Silicon Valley investors, caused a bank run as customers withdrew funds totaling $42 billion by the following day. On the morning of March 10, the California Department of Financial Protection and Innovation seized SVB and placed it under the receivership of the Federal Deposit Insurance Corporation (FDIC). An additional $100 billion were expected to be withdrawn during Friday.
Sources: en.wikipedia.org
== Studies == Ketogenic amino acids serve important roles in the human body, leading to the study of ketogenic amino acid rich (KAAR) diets as possible treatment for non-alcoholic fatty liver disease (NAFLD) and diabetes. Dietary studies of fatty liver disease in mice show that decreasing the intake of ketogenic amino acids lysine and threonine may induce hepatic steatosis, a major cause of non-alcoholic fatty liver disease. Leucine in particular has been shown to serve an important role in the metabolic pathway for insulin via activation of the rapamycin complex 1 (mTORC1) and protein S6 kinase 1 (S6K1) for which over-activation leads to insulin resistance. Further studies illustrate that ketogenic amino acid rich diets may aid in decreasing obesity and insulin resistance, but their usage remains disputed. Ketone bodies, specifically β-hydroxybutyrate (βHB) whose levels are increased while on a ketogenic diet, aid in the renewal of myelin for demyelinated axons. This renewal of myelin is important for individuals with multiple sclerosis (MS). MS is a condition which the immune system will attack the myelin sheath that insulates the nerves. Ketogenic diets are being explored as a possible remedy for this condition as the ketone bodies aid in the regeneration of myelin. Ketogenic diets are shown to alleviate diffuse axonal injury (DAI). This was tested using rats being fed a standard diet in comparison to rats being fed a ketogenic diet post DAI.
1.3 L (1,323 cc) B3-ME, I4 16-valve SOHC, FI, 73–84 PS (54–62 kW; 72–83 hp) / 104–110 N⋅m (77–81 lb⋅ft) (1994–2000) 1.5 L (1,489 cc) Z5-DE, I4 16-valve DOHC, FI, 88–110 PS (65–81 kW; 87–108 hp) / 130–137 N⋅m (96–101 lb⋅ft) (1994–2000) 1.5 L (1,489 cc) Z5-DEL, I4 16-valve DOHC, FI, lean burn, 94 PS (69 kW; 93 hp) / 132 N⋅m (97 lb⋅ft) (1996–1998) 1.5 L (1,498 cc) B5-ZE, I4 16-valve DOHC, FI, 125 PS (92 kW; 123 hp) / 129 N⋅m (95 lb⋅ft) (1994–1996) 1.6 L (1,597 cc) B6D, I4 16-valve DOHC, FI, 115 PS (85 kW; 113 hp) / 140 N⋅m (103 lb⋅ft) (1996–1998) 1.8 L (1,839 cc) BP-ZE, I4 16-valve DOHC, FI, 114–140 PS (84–103 kW; 112–138 hp) / 157–163 N⋅m (116–120 lb⋅ft) (1995–2000) Diesel:
Sivasankar and his research team have found that the mechanism behind the puzzling phenomenon is due to long-lived, force-induced hydrogen bonds. Using data from previous experiments, the team used molecular dynamics to discover that two rod-shaped cadherins in an X-dimer formed catch bonds when pulled and in the presence of calcium ions. The calcium ions keep the cadherins rigid, while pulling brings the proteins closer together, allowing for hydrogen bonds to form. The mechanism behind catch bonds helps to explain the biophysics behind cell-cell adhesion. According to the researchers, "Robust cadherin adhesion is essential for maintaining the integrity of tissue such as the skin, blood vessels, cartilage and muscle that are exposed to continuous mechanical assault." The above catch bonds are formed between adhesion receptors and ligands, and among structural molecules and motor proteins, which bear force or generate force in their physiological function. An interesting recent development is the discoveries of catch bonds formed between signaling receptors and their ligands. These include bonds between T cell antigen receptors (TCR) or pre-TCR and peptide presented by major histocompatibility complex (pMHC) molecules, Fc gamma receptor and IgG Fc, and notch receptor and ligands. The presence of catch bonds in the interactions of these signaling (rather than adhesion) receptors have been suggested to be indicative of a possible role of these receptors as mechanoreceptors.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.